BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33680718)

  • 1. Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9.
    Kou X; Ding H; Li L; Chao H
    Anal Cell Pathol (Amst); 2021; 2021():6662486. PubMed ID: 33680718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1.
    Lv T; Song K; Zhang L; Li W; Chen Y; Diao Y; Yao Q; Liu P
    Biochem Cell Biol; 2018 Oct; 96(5):663-671. PubMed ID: 29561664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
    Cai L; Zhang Q; Du L; Zheng F
    Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
    Guo J; Pan H
    Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
    Wang J; Liu L
    J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-30a-5p Enhances Cisplatin Sensitivity by Downregulating RIF1 in Ovarian Cancer.
    Yao W; Wang Y; Huang M; Zhou J; Zheng R; Jin C; Zhang Y
    Ann Clin Lab Sci; 2023 May; 53(3):418-426. PubMed ID: 37437929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer.
    Wu J; Zhang L; Wu S; Yi X; Liu Z
    Pathol Res Pract; 2020 Jul; 216(7):152979. PubMed ID: 32534701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of microRNA-3129 suppresses epithelial ovarian cancer through CD44.
    Sun X; Cui M; Tong L; Zhang A; Wang K
    Cancer Gene Ther; 2018 Dec; 25(11-12):317-325. PubMed ID: 29915283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
    Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
    Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
    Wang DY; Li N; Cui YL
    Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
    Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
    Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
    BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-205-3p Functions as a Tumor Suppressor in Ovarian Carcinoma.
    Qiao B; Wang Q; Zhao Y; Wu J
    Reprod Sci; 2020 Jan; 27(1):380-388. PubMed ID: 32046433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y; Huang S; Guo Y; Li L
    Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Yang H; Zhang X; Zhu L; Yang Y; Yin X
    DNA Cell Biol; 2021 Jun; 40(6):821-832. PubMed ID: 34030482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
    Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis.
    Xu H; Wang L; Jiang X
    Mol Cell Biochem; 2021 Feb; 476(2):1051-1061. PubMed ID: 33170430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
    Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
    Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.